Roth MKM notes that TriSalus Life Sciences (TLSI) has appointed a new Chief Financial Officer, James Young, to replace Sean Murphy, who will continue to serve the company as Chief Manufacturing, Strategy, and Business Development Officer. Young was already closely involved in the business and the firm expects “continued strong execution,” says the analyst, who reiterates a Buy rating and $11 price target on TriSalus shares.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- Roth expects ‘continued strong execution’ TriSalus under new CFO
- TriSalus Life Sciences appoints James Young CFO, Richard Marshak CCO
- TriSalus Life Sciences initiated with an Overweight at Cantor Fitzgerald
- TriSalus Life Sciences management to meet with Maxim
- TriSalus Life Sciences price target lowered to $11 from $12 at Canaccord